Literature DB >> 9505183

A case of BCG sepsis with bone marrow and liver involvement after intravesical BCG instillation.

B Dederke1, E O Riecken, T Weinke.   

Abstract

The case described concerns a 68-year-old male patient, who received intravesical BCG instillations for non-resectable urothelial carcinoma (stage pT1, G2). After the third instillation, which was complicated by hematuria during catheterization, he had a high temperature, dyspnoea, a weight-loss of 15 kg and critical recurrent hypotension for 3 weeks. On admission to the clinic he presented with high serum liver enzymes and pancytopenia. The suspected diagnosis of BCG sepsis was confirmed by the detection of typical granulomas in liver and bone marrow histology. After initiation of tuberculostatic therapy, the patient's condition improved and laboratory results returned to normal. This case shows the potential of a life-threatening systemic side effect after intravesical BCG instillation.

Entities:  

Mesh:

Year:  1998        PMID: 9505183     DOI: 10.1007/BF02768758

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  14 in total

1.  [BCG adenitis 6 years after vaccination in AIDS].

Authors:  H Blondon; T Guez; G Paul; C Truffot-Pernot; D Sicard
Journal:  Presse Med       Date:  1991-06-15       Impact factor: 1.228

2.  Treatment of malignant melanoma by intratumoral injection of BCG.

Authors:  C M Pinsky; Y Hirshaut; H F Oettgen
Journal:  Natl Cancer Inst Monogr       Date:  1973-12

3.  Pulmonary complications of intravesical Bacille Calmette-Guérin immunotherapy.

Authors:  D Israel-Biet; A Venet; D Sandron; J M Ziza; J Chretien
Journal:  Am Rev Respir Dis       Date:  1987-03

4.  Miliary tuberculosis due to intravesical bacillus Calmette-Guerin therapy.

Authors:  R C Gupta; R Lavengood; J P Smith
Journal:  Chest       Date:  1988-12       Impact factor: 9.410

Review 5.  A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer.

Authors:  S A Brosman; D L Lamm; A P van der Meijden; F M Debruyne
Journal:  Prog Clin Biol Res       Date:  1989

Review 6.  Complications of bacillus Calmette-Guérin immunotherapy.

Authors:  D L Lamm
Journal:  Urol Clin North Am       Date:  1992-08       Impact factor: 2.241

7.  A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group.

Authors:  J A Witjes; A P vd Meijden; W P Witjes; W Doesburg; H E Schaafsma; F M Debruyne
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

8.  Clinical and immunologic studies of disseminated BCG infection.

Authors:  S A Rosenberg; C Seipp; H F Sears
Journal:  Cancer       Date:  1978-05       Impact factor: 6.860

9.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Authors:  D L Lamm; P M van der Meijden; A Morales; S A Brosman; W J Catalona; H W Herr; M S Soloway; A Steg; F M Debruyne
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

10.  Granulomatous hepatitis as a late complication of BCG immunotherapy.

Authors:  T Flippin; B Mukherji; Y Dayal
Journal:  Cancer       Date:  1980-10-15       Impact factor: 6.860

View more
  5 in total

1.  "BCGitis": A rare case of tuberculous epididymo-orchitis following intravesical Bacillus Calmette-Guérin therapy.

Authors:  Virginie Demers; Vincent Pelsser
Journal:  J Radiol Case Rep       Date:  2012-11-01

2.  Fever of unknown origin and pancytopenia caused by culture-proven delayed onset disseminated bacillus Calmette-Guerin (BCG) infection after intravesical instillation.

Authors:  Pedro Dammert; Ziad Boujaoude; William Rafferty; Jonathan Kass
Journal:  BMJ Case Rep       Date:  2013-04-09

3.  Bone marrow infection with bacillus Calmette-Guérin (BCG) after intravesical immunotherapy.

Authors:  Johannes Nemeth; Brigitte Stoiser; Heide-Maria Winkler; Leonard Müllauer; Wolfgang Graninger; Stefan Winkler
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 4.  Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.

Authors:  María Asunción Pérez-Jacoiste Asín; Mario Fernández-Ruiz; Francisco López-Medrano; Carlos Lumbreras; Ángel Tejido; Rafael San Juan; Ana Arrebola-Pajares; Manuel Lizasoain; Santiago Prieto; José María Aguado
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889

5.  Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer.

Authors:  Tara Rachakonda; Brian Kendall; Adam M Spivak; Jonathan Boltax
Journal:  Open Forum Infect Dis       Date:  2017-06-17       Impact factor: 3.835

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.